Pulmonx Corp. (LUNG)

In the past six months, Pulmonx reported Q3 2025 earnings surpassing estimates but revised full-year revenue guidance downward. There was a management transition with Glen French returning as CEO and Derrick Sung appointed as COO/CFO. The company announced inducement grants, experienced analyst price target decreases, and exhibited stock volatility.

A seasonal analysis of Pulmonx Corp. stock suggests a potential pattern with a "Buy Date" of November 21 and a "Sell Date" of February 20, historically resulting in a geometric average return of 19.85% above the S&P 500. However, only five years of data are available, and the seasonal timeframe correlates poorly with the broader Healthcare sector's seasonal strength.

Pulmonx Corporation is a medical technology company focused on minimally invasive treatments for COPD, specifically severe emphysema. Their products include the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, StratX Lung Analysis Platform, and LungTraX Platform.

Pulmonx Corporation has a global presence, generating revenue through product sales to distributors and hospitals across various regions. The Zephyr Valve is commercially available in more than 25 countries, including the United States, Europe, the Middle East, Africa, and Asia Pacific.

Pulmonx Corporation generally maintains a positive brand reputation. Wall Street analysts have a "Strong Buy" consensus rating on LUNG stock. However, the company has faced financial stability concerns, reliance on product adoption, and product risks associated with the Zephyr Valve procedure.

Pulmonx Corporation's ownership is a mix of institutional, retail, and individual investors. Approximately 32.68% is held by Institutional Investors, 12.81% by Insiders, and 54.52% by Public Companies and Individual Investors. Major institutional owners include Primecap Management Co, Morgan Stanley, BlackRock, Inc., and Vanguard Group Inc.